

HOUSE BILL No. 5772

January 27, 2010, Introduced by Reps. Calley, Liss, Kurtz, McMillin, Ball and Opsommer
and referred to the Committee on Health Policy.

A bill to define and regulate certain persons managing pharmacy benefits for certain governmental entities; to provide for certain powers and duties for state departments and agencies; to provide for the certification of and imposition of regulatory and other requirements upon certain persons; and to provide for remedies and penalties.

THE PEOPLE OF THE STATE OF MICHIGAN ENACT:

1 Sec. 1. This act shall be known and may be cited as the
2 "transparency in government pharmacy benefit manager act".

3 Sec. 3. As used in this act:

4 (a) "Board" means the Michigan board of pharmacy created in
5 part 177 of the public health code, 1978 PA 368, MCL 333.17701 to
6 333.17780.

1 (b) "Commissioner" means the commissioner of the office of
2 financial and insurance regulation.

3 (c) "Covered entity" means a nonprofit hospital or medical
4 service organization; insurer; health coverage plan or health
5 maintenance organization; a health program administered by OFIR or
6 the state in the capacity of provider of health coverage; or other
7 group of persons that is a governmental entity and that provides
8 health coverage to covered individuals who are employed or reside
9 in the state and includes any person, corporation, business,
10 company, association, health care group, network, or any
11 governmental entity that provides prescription drugs or medical
12 supplies, or both. Covered entity does not include a health plan
13 that provides coverage only for accidental injury, specified
14 disease, hospital indemnity, medicare supplement, disability
15 income, long-term care, or other limited benefit health insurance
16 policies and contracts.

17 (d) "Covered individual" means a dependent or other individual
18 provided health coverage through a policy, contract, or plan by a
19 covered entity.

20 (e) "Covered person" means a member, participant, enrollee,
21 contract holder, or policyholder or beneficiary of a covered entity
22 who is provided health coverage by the covered entity.

23 (f) "Governmental entity" means the state of Michigan, a
24 school district, a state university, a county, a city, a village,
25 and a township.

26 (g) "Health benefit plan" means a policy, certificate,
27 contract, or a certificate or agreement issued by a covered entity

1 to provide, deliver, arrange for, pay for, or reimburse any of the
2 cost of health care services, including prescription drug benefits.

3 (h) "Maintenance drug" means a drug prescribed by a
4 practitioner who is licensed to prescribe drugs and used to treat a
5 medical condition for a period greater than 30 days.

6 (i) "Multisource drug" means a drug that is stocked and is
7 available from 3 or more suppliers.

8 (j) "OFIR" means the office of financial and insurance
9 regulation.

10 (k) "Person" means an individual, sole proprietorship,
11 partnership, corporation, association, organization, limited
12 liability company, or other entity.

13 (l) "Pharmacist" means that term as defined in section 17707 of
14 the public health code, 1978 PA 368, MCL 333.17707.

15 (m) "Pharmacist services" includes drug therapy and other
16 patient care services provided by a licensed pharmacist intended to
17 achieve outcomes related to the cure or prevention of a disease,
18 elimination or reduction of a patient's symptoms, or arresting or
19 slowing of a disease process as defined in the rules promulgated by
20 the board.

21 (n) "Pharmacy" means that term as defined in section 17707 of
22 the public health code, 1978 PA 368, MCL 333.17707.

23 (o) "Pharmacy benefits management" means the administration or
24 management of prescription drug benefits provided by a covered
25 entity for the benefit of covered individuals, including, but not
26 limited to, construction and management of formularies, negotiation
27 with and management of provider networks, determination of consumer

1 cost-sharing requirements, communication of benefit status to
2 consumers, claims processing, and negotiated rebates and discounts.

3 (p) "Pharmacy benefits manager" or "PBM" means a person,
4 business, or other entity that performs pharmacy benefits
5 management for covered individuals who are employed by a
6 governmental entity. PBM includes a person or entity acting for a
7 PBM in a contractual or employment relationship in the performance
8 of pharmacy benefits management regarding a covered entity.

9 (q) "Practice of pharmacy" means that term as defined in
10 section 17707 of the public health code, 1978 PA 368, MCL
11 333.17707.

12 (r) "Usual and customary price" means the price the pharmacist
13 would have charged a cash paying patient for the same services on
14 the same date inclusive of any discounts applicable, but does not
15 include a patient where reimbursement rates are set by a contract.

16 Sec. 5. (1) A person shall not act or operate, or offer to act
17 or operate, as a PBM in this state regarding prescription drugs for
18 a covered entity whose covered individuals are employed by a
19 governmental entity without a valid certificate of authority issued
20 under this act. A person failing to hold such a certificate while
21 acting as a PBM is subject to a civil fine as provided for in
22 section 31.

23 (2) A person applying for a certificate of authority to act as
24 a PBM shall file a completed application with the commissioner,
25 which application shall include or attach the following:

26 (a) All basic organizational documents of the PBM.

27 (b) The names, addresses, official positions, and professional

1 qualifications of the individuals who are responsible for the
2 conduct of the affairs of the PBM, including all members of the
3 board of directors, board of trustees, executive committee, other
4 governing board or committee, the principal officers in the case of
5 a corporation, the partners or members in the case of a partnership
6 or association, and any other person who exercises control or
7 influence over the affairs of the PBM.

8 (c) Annual statements or reports for the 3 most recent years,
9 or such other information as the commissioner may require in order
10 to review the current financial condition of the applicant.

11 (d) If the applicant is not currently acting as a PBM, a
12 statement of the amounts and sources of funds available for
13 organization expenses, and the proposed arrangements for
14 reimbursement and compensation of officers or other principals.

15 (e) The name and address of the agent for service of process
16 in the state.

17 (f) A detailed description of the claims processing services,
18 pharmacy services, insurance services, other prescription drug or
19 device services, audit procedures for network pharmacies, or other
20 administrative services to be provided.

21 (g) All incentive arrangements or programs such as rebates,
22 discounts, disbursements, or any other similar financial program,
23 or arrangement relating to income or consideration received or
24 negotiated, directly or indirectly, with any pharmaceutical
25 company, that relates to prescription drug or device services,
26 including, at a minimum, information on the formula or other method
27 for calculation and amount of the incentive arrangements, rebates,

1 or other disbursements, the identity of the associated drug or
2 device, and the dates and amounts of such disbursements.

3 (h) Such other information as the commissioner may require.

4 (i) A certificate of compliance from the board.

5 (3) The applicant shall make available for inspection by the
6 commissioner copies of all contracts with insurers, pharmaceutical
7 manufacturers, or other persons utilizing the services of the PBM
8 for pharmacy benefit management services. Certain contracts are
9 subject to approval as provided in section 9.

10 (4) The commissioner shall not issue a certificate of
11 authority if he or she determines that the PBM or any of its
12 principals or officers is not competent, trustworthy, financially
13 responsible, or of good personal and business reputation or has had
14 an insurance license or pharmacy license denied for cause by any
15 state.

16 (5) A PBM shall maintain a fidelity bond equal to at least 10%
17 of the amount of the funds handled or managed annually by the PBM.
18 However, the commissioner may require an amount in excess of
19 \$500,000.00, but not more than 10% of the amount of the funds
20 handled or managed annually by the PBM. A copy shall be provided to
21 the commissioner.

22 Sec. 7. (1) Each PBM seeking to become certificated in the
23 state must submit its plan of operation for review in a format to
24 be furnished by the commissioner. The commissioner may promulgate
25 rules under the administrative procedures act of 1969, 1969 PA 306,
26 MCL 24.201 to 24.328, to set minimum standards regarding the format
27 required, the filing fee for the certificate of compliance, the

1 requirements for recertification, and any other information that it
2 may require.

3 (2) Upon review of the submission of the plan of operation,
4 the commissioner shall determine if it complies with the rules
5 adopted under subsection (1).

6 (3) If the filing under subsection (2) meets with the
7 commissioner's approval, the commissioner shall issue a certificate
8 of compliance to the PBM. Subsequent material changes in the plan
9 of operation, as determined by the commissioner, must be filed with
10 the commissioner.

11 Sec. 9. (1) Each PBM shall disclose to the commissioner any
12 ownership interest or affiliation of any kind with any of the
13 following:

14 (a) Any insurance company responsible for providing benefits
15 directly or through reinsurance to any plan for which the PBM
16 provides services.

17 (b) Any parent companies, subsidiaries, other entities or
18 businesses relative to the provision of pharmacy services, other
19 prescription drug or device services, or a pharmaceutical
20 manufacturer.

21 (2) A PBM must notify the commissioner in writing within 5
22 calendar days of any material change in its ownership.

23 (3) A PBM shall disclose the following agreements:

24 (a) Any agreement with a pharmaceutical or device manufacturer
25 to favor the manufacturer's products or devices over a competitor's
26 products or to place the manufacturer's drug or device on any of
27 the PBM's lists or formularies, or to switch the drug or device

1 prescribed by the patient's health care provider with a drug or
2 device agreed to by the PBM and the manufacturer.

3 (b) Any agreement with a pharmaceutical manufacturer to share
4 manufacturer rebates and discounts with the PBM or to pay money or
5 other economic benefits to the PBM.

6 (c) Any agreement or practice to bill the health benefit plan
7 for prescription drugs or devices at a cost higher than that which
8 the PBM pays the pharmacy.

9 (d) Any agreement to share revenue with a mail order or
10 internet pharmacy company.

11 (e) Any agreement to sell prescription drug data, including
12 data concerning the prescribing practices of the health care
13 providers in the state.

14 (4) A PBM shall disclose all financial terms and arrangements
15 for remuneration of any kind that apply between the PBM and any
16 prescription drug or device manufacturer or labeler, including, but
17 not limited to, rebates, formulary management and drug-switch or
18 substitution programs, education support, claims processing or
19 pharmacy network fees that are charged from retail pharmacies, and
20 data sales fees.

21 Sec. 11. (1) A PBM shall maintain, for the duration of the
22 written agreement and for 2 years thereafter, books and records of
23 all transactions between the PBM, insurers, covered persons,
24 pharmacists, and pharmacies.

25 (2) The commissioner shall have access to books and records
26 maintained by the PBM for the purposes of examination, audit, and
27 inspection. The information contained in the books and records is

1 confidential. However, the commissioner may use the information in
2 any proceeding instituted against the PBM or an insurer.

3 (3) The commissioner shall conduct periodic financial
4 examinations of every PBM in this state to ensure an appropriate
5 level of regulatory oversight. The PBM shall pay the cost of the
6 examination, which shall be deposited in a special fund to provide
7 all expenses for the regulation, supervision, and examination of
8 all entities subject to regulation under this act.

9 Sec. 13. (1) Each PBM holding a certificate of authority shall
10 file with the commissioner an annual statement on or before March 1
11 of each year. The statement shall be in such form and contain such
12 matters as the commissioner prescribes and include the filing fee
13 established by rule of the commissioner. The statement shall
14 include the total number of persons subject to management by the
15 PBM during the year, the number of persons terminated during the
16 year, the number of persons covered at the end of the year, and the
17 dollar value of claims processed.

18 (2) The statement filed under subsection (1) shall disclose
19 all incentive arrangements or programs, including, at a minimum,
20 information on the formula or other method for calculation and
21 amount of the incentive arrangements, rebates, or other
22 disbursements, the identity of the associated drug or device, and
23 the dates and amounts of such disbursements. The incentive
24 arrangements include, but are not limited to, rebates, discounts,
25 disbursements, or any other similar financial program or
26 arrangement relating to income or consideration received or
27 negotiated, directly or indirectly, with any pharmaceutical

1 company, involving prescription drug or device services.

2 Sec. 15. (1) A person shall not act as a PBM for a person
3 without a written agreement between that person and the PBM.

4 (2) A PBM shall not require a pharmacist or a pharmacy to
5 participate in 1 contract in order to participate in another
6 contract and shall not exclude an otherwise qualified
7 pharmacist or pharmacy from participation in a particular network
8 solely because the pharmacist or pharmacy declined to participate
9 in another plan or network managed by the PBM.

10 (3) A PBM shall file a copy with the commissioner of all
11 agreements with pharmacies for approval by the commissioner not
12 less than 30 days before the execution of the agreement. The
13 agreement is considered approved unless the commissioner
14 disapproves it within the 30-day period.

15 (4) The written agreement between the covered entity and the
16 PBM shall not provide that the pharmacist or pharmacy is
17 responsible for the actions of the covered entity or the PBM. All
18 agreements shall provide that, when the PBM receives payment for
19 the services of the pharmacist or pharmacy, the PBM shall act as a
20 fiduciary of the pharmacy or pharmacist providing the services. The
21 PBM shall distribute the funds in accordance with the time frames
22 provided in this act and rules promulgated under this act.

23 Sec. 17. (1) When the services of a PBM are utilized, the PBM
24 shall provide a written notice approved by the covered entity to
25 covered persons advising them of the identity of, and relationship
26 between, the PBM, the covered entity, and the covered person.

27 (2) The notice in subsection (1) shall comply with all of the

1 following:

2 (a) Contain a statement advising the covered person that the
3 PBM is regulated by the OFIR and has the right to file a complaint,
4 appeal, or grievance with the commissioner concerning the PBM.

5 (b) Include the toll-free telephone number, mailing address,
6 and electronic mail address of the OFIR.

7 (c) Be written in plain English, using terms that will be
8 generally understood by the prudent layperson, and a copy must be
9 provided to the OFIR and each pharmacist or pharmacy participating
10 in the network.

11 (3) When a PBM requests a substitute prescription for a
12 prescribed drug to a covered individual, the following provisions
13 apply:

14 (a) The PBM may substitute a lower-priced generic and
15 therapeutically equivalent drug for a higher-priced prescribed
16 drug.

17 (b) With regard to substitutions in which the substitute drug
18 costs more than the prescribed drug, the substitution must be made
19 for medical reasons that benefit the covered individual. If a
20 substitution is being made under this subdivision, the PBM, after
21 disclosing to the covered individual the cost of both drugs and any
22 benefit or payment directly or indirectly accruing to the PBM as a
23 result of the substitution and any potential effects on a patient's
24 health and safety including side effects, shall obtain the approval
25 of the prescribing health professional or of that person's
26 authorized representative.

27 (c) The PBM shall transfer in full to the covered entity any

1 benefit or payment received in any form by the PBM as a result of a
2 prescription drug substitution under subdivision (a) or (b).

3 Sec. 19. (1) A PBM shall provide to a covered entity all
4 financial and utilization information requested by the covered
5 entity relating to the provision of benefits to covered individuals
6 through that covered entity and all financial and utilization
7 information relating to services to that covered entity. A PBM
8 providing information under this section may designate that
9 material as confidential. Information designated as confidential by
10 a PBM and provided to a covered entity under this section shall not
11 be disclosed by the covered entity to any person without the
12 consent to the PBM, except that disclosure may be made when
13 authorized by an order of a court of competent jurisdiction.

14 (2) A PBM shall disclose to the covered entity the following:

15 (a) All financial terms and arrangements for remuneration of
16 any kind that apply between the PBM and any prescription drug
17 manufacturer or labeler, including, but not limited to, rebates,
18 formulary management and drug-switch or substitution programs,
19 educational support, claims processing, and pharmacy network fees
20 that are charged from retail pharmacies and data sales fees.

21 (b) Whether there is a difference between the price paid to
22 retail pharmacy and the amount billed to the covered entity for a
23 prescription drug purchase.

24 (3) The covered entity may audit the PBM's books and records
25 related to the rebates or other information provided in subsections
26 (1) and (2).

27 (4) A PBM shall exercise good faith and fair dealing toward

1 the covered entity performing its duties.

2 Sec. 21. (1) A PBM shall not terminate or penalize a
3 pharmacist or pharmacy for doing any of the following:

4 (a) Filing a complaint, grievance, or appeal as permitted
5 under this act.

6 (b) Expressing disagreement with the PBM's decision to deny or
7 limit benefits to a covered person.

8 (c) Assisting a covered person to seek reconsideration of the
9 PBM's decision to deny or limit benefits.

10 (d) Discussing alternative medications.

11 (2) Prior to terminating a pharmacy or pharmacist from the
12 network, the PBM shall provide the pharmacy or pharmacist a written
13 explanation of the reason for the termination. The notice described
14 in this subsection shall be provided at least 30 days before the
15 termination date unless the termination is based on any of the
16 following:

17 (a) The loss of the pharmacy's license to practice pharmacy.

18 (b) The cancellation of the pharmacy's professional liability
19 insurance.

20 (c) Conviction of fraud as reported to the board.

21 (3) Termination of a contract between a PBM and a pharmacy or
22 pharmacist, or termination of a pharmacy or pharmacist from a PBM's
23 provider network, does not release the PBM from the obligation to
24 make any payment due to the pharmacy or pharmacist for pharmacist
25 services rendered.

26 Sec. 23. (1) PBMs shall use a current and nationally
27 recognized benchmark to base the reimbursement paid to network

1 pharmacies for medications and products. The reimbursement shall be
2 determined as follows:

3 (a) For brand or single source products, the average wholesale
4 price as listed in first data bank (Hearst publications) or facts
5 and comparisons (formerly medispan), correct and current on the
6 date of service provided, for use as an index.

7 (b) For generic drug or multisource products, maximum
8 allowable cost shall be established by referencing first data
9 bank/facts and comparisons baseline price.

10 (2) If a multisource product has no first data bank/facts and
11 comparisons baseline price, then it shall be treated as a single
12 source branded drug for the purpose of determining reimbursement.

13 Sec. 25. (1) If a PBM processes claims via electronic review,
14 then it shall electronically transmit payment within 7 calendar
15 days of that claim's transmission to the pharmacist or pharmacy.
16 Specific time limits for the PBM to pay the pharmacist for all
17 other services rendered must be set forth in the agreement.

18 (2) Within 24 hours after a price increase notification by a
19 manufacturer or supplier, the PBM shall adjust its payments to the
20 pharmacist or pharmacy consistent with the price increase.

21 (3) Claims paid by the PBM shall not be retroactively denied
22 or adjusted after 7 days from adjudication of those claims except
23 as provided in subsection (4). In no case shall acknowledgment of
24 eligibility be retroactively reversed.

25 (4) The PBM may retroactively deny or adjust under any of the
26 following circumstances:

27 (a) The original claim was submitted fraudulently.

1 (b) The original claim payment was incorrect because the
2 provider was already paid for services rendered.

3 (c) The services were not rendered by the pharmacist or
4 pharmacy.

5 (5) The PBM may not require extrapolation audits as a
6 condition of participating in the contract, network, or program.

7 (6) The PBM shall not recoup any money that it believes is due
8 as a result of the audit by setoff until the pharmacist or pharmacy
9 has the opportunity to review the PBM's findings and concurs with
10 the results. If the parties cannot agree, then the audit shall be
11 subject to review by the commission.

12 Sec. 27. (1) A PBM shall not intervene in the delivery or
13 transmission of prescriptions from the prescriber to the pharmacist
14 or pharmacy for the purpose of doing any of the following:

15 (a) Influencing the prescriber's choice of therapy.

16 (b) Influencing the patient's choice of pharmacist or
17 pharmacy.

18 (c) Altering the prescription information, including, but not
19 limited to, switching the prescribed drug without the express
20 authorization of the prescriber.

21 (2) An agreement shall not mandate that a pharmacist or
22 pharmacy change a covered person's prescription unless the
23 prescribing physician and the covered person authorize the
24 pharmacist to make the change.

25 (3) The covered entity and the PBM may not discriminate with
26 respect to participation in the network or reimbursement as to any
27 pharmacist or pharmacy that is acting within the scope of its

1 license.

2 (4) The PBM may not transfer a health benefit plan to another
3 payment network unless it receives written authorization from the
4 insurer.

5 (5) A PBM shall not discriminate when contracting with
6 pharmacies on the basis of copayments or days of supply. A contract
7 shall apply the same coinsurance, copayment, and deductible to
8 covered drug prescriptions filled by any pharmacy, including a mail
9 order pharmacy or pharmacist who participates in the network.

10 (6) A PBM shall not discriminate when advertising the names of
11 pharmacies that are participating. Any list of participating
12 pharmacies shall be complete and all-inclusive.

13 (7) A PBM shall not mandate on any pharmacist or pharmacy
14 basic record keeping that is more stringent than that required by
15 state or federal laws, rules, or regulations.

16 Sec. 29. (1) The commission shall promulgate rules under the
17 administrative procedures act of 1969, 1969 PA 306, MCL 24.201 to
18 24.328, for formal investigation of complaints concerning the
19 failure of a PBM to comply with this act.

20 (2) Any complaint shall be resolved and determined under the
21 administrative procedures act of 1969, 1969 PA 306, MCL 24.201 to
22 24.328.

23 Sec. 31. A person failing to hold a certificate of authority
24 issued under this act while acting as a PBM is subject to a civil
25 fine of not less than \$5,000.00 or more than \$10,000.00 for each
26 violation.

27 Sec. 33. (1) All benefits payable under a pharmacy benefits

1 management plan shall be paid as soon as feasible but not less than
2 7 days after receipt of a clean claim when the claim is submitted
3 electronically.

4 (2) Payments to the pharmacy or pharmacist for clean claims
5 are considered to be overdue if not paid within 7 days. If any
6 clean claim is not timely paid, the pharmacy benefits manager must
7 pay the pharmacy or pharmacist interest at the rate of 10% per
8 annum commencing the day after any claim payment or portion thereof
9 was due until the claim is finally settled or adjudicated in full.

10 Sec. 35. Compensation to a PBM for any claims that the PBM
11 adjusts or settles on behalf of an insurer is not contingent on
12 claims experience. This section does not prohibit the compensation
13 of a PBM based on total number of claims paid or processed.

14 Sec. 37. The commissioner may promulgate rules under the
15 administrative procedures act of 1969, 1969 PA 306, MCL 24.201 to
16 24.328, to carry out the provisions of this act. The rules may
17 include the definition of terms, use of prescribed forms, reporting
18 requirements, prohibited practices, administrative fines, license
19 sanctions, and enforcement procedures.

20 Sec. 39. This act takes effect October 1, 2011.